United Therapeutics Corp (UTHR) trades on Nasdaq and is classified in the Technology sector. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue. This page tracks UTHR using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$543.40
Volume
883,178
52-week range
$409.07 – $609.35
Market cap
$23.31B
Source: Polygon (snapshot) · Verified Oct 14, 2026, 6:06 PM EDT
1D
-0.62%
1W
-0.91%
1M
+7.43%
1Y
+24.54%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Aug 4, 2026, 8:00 PM EDT
P/E (trailing)
Reported Q2'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)
P/E (forward, est.)
Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Nov 3, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $783.3M · Diluted EPS 7.27
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | 7.27 | 6.97 | +4.3% |
| 2026-03-31 | 5.82 | 7.01 | -16.9% |
| 2025-12-31 | 7.70 | 7.33 | +5.1% |
| 2025-09-30 | 7.16 | 7.33 | -2.3% |
Bear $194.40 · Base $243.00 · Bull $291.60 — Significantly Overvalued versus the last verified price.
Sustained growth and margin strength support roughly $291.60.
Current reported earnings power maps to roughly $243.00 (significantly overvalued versus the last verified price).
Multiple compression or slowing growth maps to roughly $194.40.
Calculated from verified reported financials and the last verified price (data verified Oct 14, 2026, 6:06 PM EDT). Analytical model output, not a price target or investment advice.
Rating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
22
Source: finnhub
Zacks Investment Research · Oct 14, 2026
Yahoo Finance · Oct 14, 2026
Benzinga · Oct 13, 2026
Zacks Investment Research · Oct 14, 2026
Yahoo Finance · Oct 14, 2026
Yahoo Finance · Oct 13, 2026
Some data is delayed, stale or unavailable. Everything shown is still verified.
Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
United Therapeutics Corp trades under the ticker UTHR on Nasdaq.
UTHR was last verified at $540.03 (-0.62% on the day). After hours, last verified Oct 14, 2026, 6:06 PM EDT. Market data may be delayed and is shown with its own timestamp.
Based on the latest reported financials, UTHR revenue changed -1.9% year over year (filed Aug 4, 2026).
The next confirmed UTHR earnings date is Nov 3, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
For Q2'26, UTHR reported revenue of $783.3M and diluted EPS of 7.27.
Ticker-Terminal scores UTHR at 54/100 (F) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.
Create a free Ticker-Terminal account to run a full AI research report on UTHR — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from UTHR's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 14, 2026, 6:27 PM EDT.